These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis. Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805 [TBL] [Abstract][Full Text] [Related]
27. Assessment of disseminated adenovirus infections using quantitative plasma PCR in adult allogeneic stem cell transplant recipients receiving reduced intensity or myeloablative conditioning. Kalpoe JS; van der Heiden PL; Barge RM; Houtzager S; Lankester AC; van Tol MJ; Kroes AC Eur J Haematol; 2007 Apr; 78(4):314-21. PubMed ID: 17331130 [TBL] [Abstract][Full Text] [Related]
28. Ex vivo T-cell-depleted allogeneic stem cell transplantation for hematologic malignancies: The search for an optimum transplant T-cell dose and T-cell add-back strategy. Anandi P; Tian X; Ito S; Muranski P; Chokshi PD; Watters N; Chawla U; Hensel N; Stroncek DF; Battiwalla M; Barrett AJ Cytotherapy; 2017 Jun; 19(6):735-743. PubMed ID: 28395942 [TBL] [Abstract][Full Text] [Related]
29. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with Fanconi anemia. Zecca M; Strocchio L; Pagliara D; Comoli P; Bertaina A; Giorgiani G; Perotti C; Corbella F; Brescia L; Locatelli F Biol Blood Marrow Transplant; 2014 Apr; 20(4):571-6. PubMed ID: 24462983 [TBL] [Abstract][Full Text] [Related]
30. Cytomegalovirus Viral Load Kinetics Predict Cytomegalovirus End-Organ Disease and Mortality After Hematopoietic Cell Transplant. Stern A; Su Y; Dumke H; Fang J; Tamari R; Jakubowski A; Cho C; Giralt S; Perales MA; Papanicolaou GA J Infect Dis; 2021 Aug; 224(4):620-631. PubMed ID: 33864371 [TBL] [Abstract][Full Text] [Related]
31. Fludarabine and exposure-targeted busulfan compares favorably with busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity. Bartelink IH; van Reij EM; Gerhardt CE; van Maarseveen EM; de Wildt A; Versluys B; Lindemans CA; Bierings MB; Boelens JJ Biol Blood Marrow Transplant; 2014 Mar; 20(3):345-53. PubMed ID: 24315842 [TBL] [Abstract][Full Text] [Related]
33. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Myers GD; Bollard CM; Wu MF; Weiss H; Rooney CM; Heslop HE; Leen AM Bone Marrow Transplant; 2007 Jun; 39(11):677-86. PubMed ID: 17417664 [TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation. Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578 [TBL] [Abstract][Full Text] [Related]
35. Burden of adenoviraemia predicts survival in paediatric recipients of allogeneic haematopoietic stem cell transplant. Deambrosis D; Davies E; Turner A; Guiver M; Bonney D; Campbell H; Wynn RF; Hiwarkar P J Clin Virol; 2020 Jun; 127():104373. PubMed ID: 32330815 [TBL] [Abstract][Full Text] [Related]
36. Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience. Verdeguer A; de Heredia CD; González M; Martínez AM; Fernández-Navarro JM; Pérez-Hurtado JM; Badell I; Gómez P; González ME; Muñoz A; Díaz MA; Bone Marrow Transplant; 2011 Jan; 46(1):119-24. PubMed ID: 20228849 [TBL] [Abstract][Full Text] [Related]
37. Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis. Inamoto Y; Takeda W; Hirakawa T; Sakaguchi H; Nakano N; Uchida N; Doki N; Ikegame K; Katayama Y; Sawa M; Kuriyama T; Hiramoto N; Ota S; Ozawa Y; Kataoka K; Kanda Y; Hino M; Kimura T; Atsuta Y; Fukuda T; Nagafuji K Am J Hematol; 2022 Dec; 97(12):1568-1579. PubMed ID: 36087061 [TBL] [Abstract][Full Text] [Related]
38. Prospective monitoring of adenovirus infection and type analysis after allogeneic hematopoietic cell transplantation: A single-center study in Korea. Kang JM; Park KS; Kim JM; Huh HJ; Ki CS; Lee NY; Yoo KH; Sung KW; Koo HH; Kim YJ Transpl Infect Dis; 2018 Jun; 20(3):e12885. PubMed ID: 29569813 [TBL] [Abstract][Full Text] [Related]
39. Clinical manifestations, prognostic factors, and outcomes of adenovirus pneumonia after allogeneic hematopoietic stem cell transplantation. Wang Y; Zhang X; Xu L; Wang Y; Yan C; Chen H; Chen Y; Wei F; Han W; Wang F; Wang J; Huang X; Mo X Virol J; 2024 May; 21(1):110. PubMed ID: 38745209 [TBL] [Abstract][Full Text] [Related]
40. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Feucht J; Opherk K; Lang P; Kayser S; Hartl L; Bethge W; Matthes-Martin S; Bader P; Albert MH; Maecker-Kolhoff B; Greil J; Einsele H; Schlegel PG; Schuster FR; Kremens B; Rossig C; Gruhn B; Handgretinger R; Feuchtinger T Blood; 2015 Mar; 125(12):1986-94. PubMed ID: 25617426 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]